ReviewFrontiers in oncology2026
Radionuclide theranostics: advances and clinical applications in lung cancer.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer remains a leading cause of global cancer deaths, underscoring the urgent need for more accurate diagnostic and treatment approaches. Radionuclide theranostics has rapidly emerged as a paradigm that couples molecular imaging with targeted internal irradiation, enabling personalized cancer care. This review provides a systematic overview of radionuclide theranostics in lung cancer. We first summarize core theranostic principles, including the classes of diagnostic and therapeutic radionuclides and their mechanisms of action. We then emphasize target selection, discussing key molecular targets overexpressed in lung tumors and within the tumor microenvironment that are suitable for radiopharmaceutical development. We synthesize clinical translational evidence by collating efficacy and safety outcomes from pivotal studies and highlighting candidate agents currently in clinical trials. We also examine patient stratification, combination strategies, and the management of treatment-related toxicities. Finally, we outline major challenges, such as target heterogeneity, uncertainties in optimal dosing, and incomplete toxicity profiling, and propose future directions to optimize ligand design, expand target and radionuclide repertoires, and integrate radionuclide therapy with other treatment modalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.